Glaukos (GKOS) Stock Price, News & Analysis

Glaukos logo
$238.17 +5.09 (+2.18%)
Closing price 11/19/2026
Extended Trading
$240.25 +2.08 (+0.87%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Glaukos Stock (NYSE:GKOS)

Advanced

Key Stats

Today's Range
$231.61
▼
$239.34
50-Day Range
$153.63
▼
$248.00
52-Week Range
$93.78
▼
$255.18
Volume
744,956 shs
Average Volume
1.92 million shs
Market Capitalization
$14.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.00
Consensus Rating
Moderate Buy

Company Overview

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period.

The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea. Glaukos was founded in 1998 and helped establish the MIGS category as an alternative to traditional glaucoma surgery.

Based in Aliso Viejo, California, Glaukos serves eye-care professionals and patients in the United States and internationally. Its products are distributed in multiple markets, with availability varying by country and regulatory approval.

AI Generated. May Contain Errors.

Glaukos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

GKOS MarketRank™: 
2.75821917808 of 5 stars

Glaukos scored higher than 55% of companies evaluated by MarketBeat, and ranked 412th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Glaukos has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 13 buy ratings, 1 hold rating, and 1 sell rating.

  • Downside Risk

    Glaukos has a consensus price target of $218.00, representing about 8.5% downside from its current price of $238.17.

  • Amount of Analyst Coverage

    Glaukos has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Glaukos' stock forecast and price target.
  • Earnings Growth

    Earnings for Glaukos are expected to grow by 202.00% in the coming year, from $0.50 to $1.51 per share.

  • Price to Book Value per Share Ratio

    Glaukos has a P/B Ratio of 19.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.05% of the float of Glaukos has been sold short.
  • Short Interest Ratio / Days to Cover

    Glaukos has a short interest ratio ("days to cover") of 2.85, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Glaukos has recently increased by 3.24%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Glaukos does not currently pay a dividend.

  • Dividend Growth

    Glaukos does not have a long track record of dividend growth.

  • News Sentiment

    Glaukos has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Glaukos this week, compared to 5 articles on an average week.
  • Search Interest

    10 people have searched for GKOS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
  • MarketBeat Follows

    7 people have added Glaukos to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Glaukos insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,386,705.00 in company stock.

  • Percentage Held by Insiders

    5.90% of the stock of Glaukos is held by insiders.

  • Percentage Held by Institutions

    99.04% of the stock of Glaukos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Glaukos' insider trading history.
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Stock: Insider Joseph Gilliam Sells 861 Shares
Glaukos (GKOS) Stock May Be 33% Below Fair Value On Cash Flow
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Glaukos (GKOS) Has Investors Asking A Bigger Question
Glaukos (NYSE:GKOS) Stock Price Expected to Rise, BTIG Research Analyst Says
Glaukos (NYSE:GKOS) COO Sells $11,063,955.44 in Stock
See More Headlines

GKOS Stock Analysis - Frequently Asked Questions

Glaukos' stock was trading at $112.80 at the beginning of 2026. Since then, GKOS stock has increased by 111.1% and is now trading at $238.17.

Glaukos Corporation (NYSE:GKOS) posted its quarterly earnings results on Wednesday, October, 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.57. The firm's revenue for the quarter was up 58.0% on a year-over-year basis.
Read the conference call transcript
.

Glaukos (GKOS) raised $99 million in an initial public offering on Thursday, June 25th 2015. The company issued 6,000,000 shares at $16.00-$17.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Top institutional investors of Glaukos include State Street Corp (3.91%), Goldman Sachs Group Inc. (1.73%), William Blair Investment Management LLC (1.10%) and Anomaly Capital Management LP (0.88%). Insiders that own company stock include Thomas William Burns, Tomas Navratil, Joseph E Gilliam, Alex R Thurman, Marc Stapley, Gilbert H Kliman, Mark J Foley, Leana Wen and Aimee S Weisner.
View institutional ownership trends
.

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Glaukos investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Taiwan Semiconductor Manufacturing (TSM), Tesla (TSLA), Micron Technology (MU) and NeoGenomics (NEO).

Company Calendar

Last Earnings
10/28/2026
Today
11/19/2026
38th Annual Healthcare Conference
12/01/2026
Citi Annual Global Healthcare Conference 2026
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSE:GKOS
CIK
1192448
Employees
1,094
Year Founded
1998

Price Target and Rating

High Price Target
$255.00
Low Price Target
$138.00
Potential Upside/Downside
-8.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
16 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$187.69 million
Net Margins
-24.60%
Pretax Margin
-25.28%
Return on Equity
-0.97%
Return on Assets
-0.71%

Debt

Debt-to-Equity Ratio
0.09
Current Ratio
4.57
Quick Ratio
4.09

Sales & Book Value

Annual Sales
$507.44 million
Price / Sales
27.79
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.12 per share
Price / Book
19.65

Miscellaneous

Outstanding Shares
59,200,000
Free Float
55,704,000
Market Cap
$14.10 billion
Optionable
Optionable
Beta
0.68

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NYSE:GKOS) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners